951 results match your criteria Pityriasis Rubra Pilaris

Paraneoplastic Pityriasis Rubra Pilaris Preceding Leukemia.

Adv Skin Wound Care 2022 Jun;35(6):1-4

Paul Vance, DO, is Resident Physician, Piedmont Healthcare, Macon, Georgia. At the Mayo Clinic, Rochester, Minnesota, Saranya Wyles, MD, PhD, is Resident Physician and Afsaneh Alavi, MD, is Consultant Physician. The authors have disclosed no financial relationships related to this article. Submitted June 15, 2021; accepted in revised form July 30, 2021.

Abstract: Pityriasis rubra pilaris (PRP) is a rare, chronic papulosquamous disorder that presents with scaling plaques, palmoplantar keratoderma, and keratotic follicular papules. Typically, there are distinctive unaffected areas referred to as "islands of sparing." Pityriasis rubra pilaris has been associated with various immunodeficient states and malignancies. Read More

View Article and Full-Text PDF

Secukinumab for the Treatment of Adult-Onset Pityriasis Rubra Pilaris: A Single-Arm Clinical Trial with Transcriptomic Analysis.

Br J Dermatol 2022 Jun 14. Epub 2022 Jun 14.

Department of Dermatology, Mayo Clinic, Jacksonville, Florida, USA.

Background: The pathogenesis of pityriasis rubra pilaris (PRP) is not completely understood, but IL-17 has been shown to play a critical role. There are no reliable immunomodulatory agents to treat PRP. We conducted an open-label, single-arm clinical trial of secukinumab, a monoclonal antibody that inhibits IL-17A, for the treatment of PRP. Read More

View Article and Full-Text PDF

Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes.

Curr Opin Rheumatol 2022 Jun 10. Epub 2022 Jun 10.

Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma, Barcelona, Spain.

Purpose Of Review: Psoriasis vulgaris is the commonest presentation of psoriatic disease, but morphologic variants such as pustular psoriasis (PP) and a closely related disease, pityriasis rubra pilaris (PRP), have been known for a long time, have been associated with rheumatologic manifestations indistinguishable from psoriatic arthritis (PsA) that may go unrecognized, and often represent a therapeutic conundrum. There is recent evidence that underlying genetic and pathogenetic differences may provide the basis for newer therapeutic approaches.

Recent Findings: This narrative review highlights the clinical, genetic and pathogenetic characteristics of PP and PRP, their association with PsA and recent developments in their treatment, especially with biologic agents targeting IL-36 and other cytokines of pathogenic relevance. Read More

View Article and Full-Text PDF

Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor.

Skin Health Dis 2021 Dec 20;1(4):e71. Epub 2021 Oct 20.

St Vincent's Hospital Sydney New South Wales Australia.

Sarcoidosis is a non-infective granulomatous disorder of unknown aetiology, with cutaneous involvement affecting up to 30% of patients. Drug-induced sarcoidosis has been reported secondary to modern melanoma therapies including immune-checkpoint inhibitors and first generation BRAF inhibitors such as vemurafenib and dabrafenib. Herein, we report a case of cutaneous micropapular sarcoidosis that first developed on immune-checkpoint inhibition with ipilimumab and nivolumab for metastatic melanoma, which was exacerbated and further complicated by pityriasis rubra pilaris-like palmar plaques upon transition to a next-generation BRAF-dimerisation inhibitor. Read More

View Article and Full-Text PDF
December 2021

[Translated article] Facial Discoid Dermatosis: A New Variant of Pityriasis Rubra Pilaris?

Actas Dermosifiliogr 2022 May 30. Epub 2022 May 30.

Servicio de Dermatología, Hospital do Meixoeiro, EOXI, Vigo, Pontevedra, Spain.

View Article and Full-Text PDF

Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review.

JAAD Case Rep 2022 Jun 1;24:97-100. Epub 2022 Apr 1.

Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.

View Article and Full-Text PDF

Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection.

J Eur Acad Dermatol Venereol 2022 May 10. Epub 2022 May 10.

Department of Dermatology, Christian Hospital Unna, Unna, Germany.

View Article and Full-Text PDF

A case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine.

JAAD Case Rep 2022 Jun 2;24:74-77. Epub 2022 May 2.

Department of Dermatology, Monash Health, Clayton, Victoria, Australia.

View Article and Full-Text PDF

Pityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine.

JAAD Case Rep 2022 May 1;23:114-116. Epub 2022 Apr 1.

Department of Dermatology, Medical College of Georgia, Augusta University, Augusta, Georgia.

View Article and Full-Text PDF

A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report.

SAGE Open Med Case Rep 2022 19;10:2050313X221093453. Epub 2022 Apr 19.

Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

Classic adult pityriasis rubra pilaris is a severe papulosquamous disease that tends to resolve in 3-5 years but can have a devastating impact on patients while active. It shares features with psoriasis, but treatment remains largely empiric, based on case reports and series. The condition is often refractory to treatment, especially initially, with topical corticosteroids and oral acitretin the more commonly employed agents. Read More

View Article and Full-Text PDF

Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: Decoding a possible trigger!!

J Cosmet Dermatol 2022 Mar 25. Epub 2022 Mar 25.

Department of Dermatology, Venereology and Leprology, Sardar Patel Medical College, Bikaner, Rajasthan, India.

View Article and Full-Text PDF

Pityriasis rubra pilaris in association with inactivated SARS-CoV-2 vaccine (CoronaVac).

Dermatol Ther 2022 Jun 28;35(6):e15455. Epub 2022 Mar 28.

Universidad Autónoma de Nuevo León, Hospital Universitario "Dr. José Eleuterio González", Dermatology Department, Monterrey, Nuevo León, Mexico.

View Article and Full-Text PDF

[Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?]

Hautarzt 2022 Mar 16. Epub 2022 Mar 16.

Zentrum für Dermatologie, Allergologie und Dermatochirurgie, Helios Universitätsklinikum Wuppertal, Universität Witten/Herdecke, Heusnerstr. 40, 42283, Wuppertal, Deutschland.

Numerous cutaneous side effects associated with COVID-19 vaccines have been described since their clinical approval. These include, among others, injection site reactions, urticarial, maculopapular and pityriasiform rashes or temporary exacerbations of a pre-existing chronic inflammatory skin disease. Herein we report about three cases of pityriasis rubra pilaris that occurred for the first time in close temporal relationship with the administration of a COVID-19 vaccine. Read More

View Article and Full-Text PDF

Dermoscopy of Gottron's papules and other inflammatory dermatoses involving the dorsa of the hands.

J Eur Acad Dermatol Venereol 2022 Jul 19;36(7):1080-1087. Epub 2022 Mar 19.

Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów, Poland.

Background: Several inflammatory dermatoses, including dermatomyositis (DM), may present as erythematous papules or plaques on the dorsal aspects of the hands over the joints. Limited skin involvement in these entities may pose a diagnostic challenge. (Video)dermoscopy is being utilized more frequently to aid in the differential diagnosis of inflammatory skin conditions. Read More

View Article and Full-Text PDF

Clinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody.

Br J Dermatol 2022 Mar 8. Epub 2022 Mar 8.

Department of Dermatology, Venereology and Allergology.

Here we present another family with CARD14-associated papulosquamous eruption, which is characterized by mutations in CARD14 and skin lesions resembling psoriasis and pityriasis rubra pilaris. We show beneficial therapeutic response to anti-IL17A treatment in one patient and performed immunomonitoring of our patient, exhibiting enhanced pSTAT3 levels in T cells before treatment, which normalized after treatment. Together, our data support the pathogenic role of IL-17A in this disease, which might have consequences for future treatment decisions in this rare condition. Read More

View Article and Full-Text PDF

Comment on: 'Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine'.

Clin Exp Dermatol 2022 06 26;47(6):1195-1196. Epub 2022 Mar 26.

Department of Community Medicine, Dr DY Patil University, Pune, India.

View Article and Full-Text PDF

Coincidence of Bullous Pemphigoid and Pityriasis Rubra Pilaris.

Acta Derm Venereol 2022 Mar 22;102:adv00674. Epub 2022 Mar 22.

Dermatology, venereology and allergy, Medical University of Innsbruck, Innsbruck, Austria.

View Article and Full-Text PDF

A novel presentation of juvenile pityriasis rubra pilaris with possible involvement of bacterial superantigens.

J Dtsch Dermatol Ges 2022 03 2;20(3):335-337. Epub 2022 Feb 2.

Dermatology Unit, IRCSS Policlinico di S. Orsola, Bologna, Italy.

View Article and Full-Text PDF

Rapidly Progressive Erythroderma.

Am Fam Physician 2022 01;105(1):75-76

Largo Medical Center, Largo, FL, USA.

View Article and Full-Text PDF
January 2022

Clinical Patterns and Clinicopathologic Correlation of 100 Patients with Erythroderma in a Tertiary Care Institute in India.

Skinmed 2021 1;19(6):440-450. Epub 2021 Dec 1.

Department of Dermatology, Venereology & Leprology PGIMER, Chandigarh, India.

Erythroderma is a severe dermatologic manifestation of a variety of diseases. We analyzed the clinical parameters and the clinicopathologic correlation in patients with erythroderma. Consecutive patients diagnosed with erythroderma at a tertiary care institute were evaluated for 5 years. Read More

View Article and Full-Text PDF
January 2022

Epithelioid cell granuloma formation in CARD14-associated papulosquamous eruptions.

J Eur Acad Dermatol Venereol 2022 05 29;36(5):e369-e371. Epub 2021 Dec 29.

Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

View Article and Full-Text PDF

The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin.

Clin Dermatol 2021 Nov-Dec;39(6):966-984. Epub 2021 Jul 25.

Discovery Life Sciences, Powell, Ohio; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

A total of 22 patients who had developed an adverse cutaneous reaction to the Moderna or Pfizer vaccine underwent biopsies. Each patient was assessed light microscopically, and, in select biopsies, spike glycoprotein and cytokine assessment were also conducted. The patients developed self-limited cutaneous reactions often described clinically as urticarial or eczematous within 1 day to 4 weeks after receiving the first or second dose of the Pfizer or Moderna vaccine. Read More

View Article and Full-Text PDF
December 2021

Successful treatment of pityriasis rubra pilaris with tildrakizumab.

Australas J Dermatol 2022 Feb 2;63(1):120-121. Epub 2021 Dec 2.

Department of Dermatology, Concord Repatriation General Hospital, Sydney, Australia.

View Article and Full-Text PDF
February 2022

Atypical Presentation of Pityriasis Rubra Pilaris: Challenges in Diagnosis and Management.

Cutis 2021 Sep;108(3):E33-E35

Dr. Abrouk is from the School of Medicine, University of California, Irvine. Drs. Nakamura, Koo, and Bhutani are from the Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco. Dr. Zhu is from the Keck School of Medicine, University of Southern California, Los Angeles. Dr. Farahnik is from the College of Medicine, University of Vermont, Burlington.

View Article and Full-Text PDF
September 2021

The histopathological landscape of the major psoriasiform dermatoses.

Arch Clin Cases 2019 27;6(3):59-68. Epub 2021 Oct 27.

Department of Morphofunctional Sciences I - Histology, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.

Psoriasiform dermatoses represent a wide spectrum of inflammatory conditions, with several major forms represented by psoriasis, as the prototype of this category, followed by pustular psoriasis, Reiter's syndrome, pityriasis rubra pilaris, lichen simplex chronicus and large-plaques parapsoriasis. They create a diagnostic challenge, both clinical and histopathological, because of their complexity and frequent overlapping of the microscopical features. The characteristic histopathological features of psoriasiform reaction comprise extensive hyperkeratosis, with horizontally confluent but vertically intermittent parakeratosis, which alternate with orthokeratosis, thin granular layer, with relative frequent mitoses, uniform elongated and fused rete ridges, edematous superficial papillary dermis, with dilated capillaries, perivascular lymphocytic infiltrate, Munro's microabscesses, and spongiform pustules of Kogoj. Read More

View Article and Full-Text PDF
October 2021

Trachyonychia with Juvenile Pityriasis Rubra Pilaris.

Indian Dermatol Online J 2021 Sep-Oct;12(5):758-759. Epub 2021 Aug 2.

Department of Dermatology and Venereology, All India Institute of Medical Sciences, Delhi, India.

View Article and Full-Text PDF